A new therapy now exists to treat the breast cancer advanced triple negative. Trodelvy (sacituzumab govitecan) is a drug in the class of anticancer. After a favorable opinion issued by theNational Medicines Safety Agency, obtaining early access to this drug was recently granted by HAS (High Authority of Health) under very specific conditions. This new class of anticancer drugs, which combine a antibody and an chemotherapy, is recommended in the breast cancer triple negative metastasis for patients who have received two or more systemic lines of treatment that have not worked.
What is triple negative breast cancer?
Breast cancers ” triple negative »Correspond to a group of tumors that do not have the cell receptors usually found in the gland breast. These are hormone receptors (estrogen (RE) and progesterone (RP)) and receivers for a protein regulating cell multiplication: HER2 (RHER2). They are therefore RE-, RP- and RHER2-, hence the term triple negative. They represent 10 to 15% of breast cancers.
More aggressive and with a risk of the appearance of metastases increased, this type of cancer is not eligible for treatments targeting these three markers (hormone therapy). When the chemotherapy is not effective, the possibility of having targeted therapy (Parp inhibitor involved in the repair process of theDNA) concerns only 15% of cases. The other patients are therefore waiting for a new effective therapeutic line.
Trodelvy: a new therapeutic strategy
Trodelvy is an association of a monoclonal antibody directed against a protein expressed on the surface of epithelial cells and overexpressed in triple negative breast cancer. It is conjugated with SN-38, the active ingredient in irinotecan (anticancer).
A clinical study international phase III on nearly 500 patients (Ascent study) demonstrated the effectiveness of this new drug with a progression-free increase in overall survival of 5.7 months compared to conventional chemotherapy treatment. The antibody-conjugated drug combination brings chemotherapy to the heart of tumor cells.
Currently indicated in the United States in triple negative breast cancer and cancer of the urinary tract metastasis, Troveldy therefore meets the necessary criteria to offer a therapeutic option for this type of cancer. It treats serious and disabling illnesses and to date there are no other treatments for this type of indication. It nevertheless has serious effects secondary such as neutropenia and diarrhea severe which can threaten the prognosis vital.
You will also be interested
[EN VIDÉO] What are the different effective treatments for breast cancer? Breast cancer is the most common cancer in women. In 2012, around 48,000 people developed this cancer and nearly 9 out of 10 people were cured of it. The University Hospitals of Geneva explain to us during this film how the treatment takes place.
Interested in what you just read?
.
fs7